Drug discovery for G-protein coupled receptors (GPCRs) faces challenges due to high attrition rates, stemming from inefficient screening and validation processes. Identifying novel therapeutic compounds targeting GPCRs is difficult using traditional methods.

Seven Biosciences develops drug discovery platforms specifically designed to improve the identification of novel therapeutic compounds targeting GPCRs. Their technology aims to address the high attrition rates in drug development by providing more efficient and effective screening and validation processes. By focusing on GPCRs, Seven Biosciences seeks to streamline the drug discovery pipeline, enabling the faster and more reliable identification of promising drug candidates. This approach has the potential to reduce the time and cost associated with bringing new GPCR-targeted drugs to market.

GPCR-focused drug discovery platform

Enhanced screening processes for identifying potential drug candidates

Improved validation methods to reduce attrition rates

The primary target audience includes pharmaceutical companies and research institutions involved in drug discovery, particularly those focused on developing therapeutics targeting GPCRs.